Richard Body1, Gillian Burrows2, Simon Carley3, Philip S Lewis2. 1. The University of Manchester, Manchester, UK Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. 2. Stockport NHS Foundation Trust, Manchester, UK. 3. Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK Manchester Metropolitan University, Manchester, UK.
Abstract
OBJECTIVE: The Manchester Acute Coronary Syndromes (MACS) decision rule may enable acute coronary syndromes to be immediately 'ruled in' or 'ruled out' in the emergency department. The rule incorporates heart-type fatty acid binding protein (h-FABP) and high sensitivity troponin T levels. The rule was previously validated using a semiautomated h-FABP assay that was not practical for clinical implementation. We aimed to validate the rule with an automated h-FABP assay that could be used clinically. METHODS: In this prospective diagnostic cohort study we included patients presenting to the emergency department with suspected cardiac chest pain. Serum drawn on arrival was tested for h-FABP using an automated immunoturbidimetric assay (Randox) and high sensitivity troponin T (Roche). The primary outcome, a diagnosis of acute myocardial infarction (AMI), was adjudicated based on 12 h troponin testing. A secondary outcome, major adverse cardiac events (MACE; death, AMI, revascularisation or new coronary stenosis), was determined at 30 days. RESULTS: Of the 456 patients included, 78 (17.1%) had AMI and 97 (21.3%) developed MACE. Using the automated h-FABP assay, the MACS rule had the same C-statistic for MACE as the original rule (0.91; 95% CI 0.88 to 0.92). 18.9% of patients were identified as 'very low risk' and thus eligible for immediate discharge with no missed AMIs and a 2.3% incidence of MACE (n=2, both coronary stenoses). 11.1% of patients were classed as 'high-risk' and had a 92.0% incidence of MACE. CONCLUSIONS: Our findings validate the performance of a refined MACS rule incorporating an automated h-FABP assay, facilitating use in clinical settings. The effectiveness of this refined rule should be verified in an interventional trial prior to implementation. TRIAL REGISTRATION NUMBER: UK CRN 8376. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: The Manchester Acute Coronary Syndromes (MACS) decision rule may enable acute coronary syndromes to be immediately 'ruled in' or 'ruled out' in the emergency department. The rule incorporates heart-type fatty acid binding protein (h-FABP) and high sensitivity troponin T levels. The rule was previously validated using a semiautomated h-FABP assay that was not practical for clinical implementation. We aimed to validate the rule with an automated h-FABP assay that could be used clinically. METHODS: In this prospective diagnostic cohort study we included patients presenting to the emergency department with suspected cardiac chest pain. Serum drawn on arrival was tested for h-FABP using an automated immunoturbidimetric assay (Randox) and high sensitivity troponin T (Roche). The primary outcome, a diagnosis of acute myocardial infarction (AMI), was adjudicated based on 12 h troponin testing. A secondary outcome, major adverse cardiac events (MACE; death, AMI, revascularisation or new coronary stenosis), was determined at 30 days. RESULTS: Of the 456 patients included, 78 (17.1%) had AMI and 97 (21.3%) developed MACE. Using the automated h-FABP assay, the MACS rule had the same C-statistic for MACE as the original rule (0.91; 95% CI 0.88 to 0.92). 18.9% of patients were identified as 'very low risk' and thus eligible for immediate discharge with no missed AMIs and a 2.3% incidence of MACE (n=2, both coronary stenoses). 11.1% of patients were classed as 'high-risk' and had a 92.0% incidence of MACE. CONCLUSIONS: Our findings validate the performance of a refined MACS rule incorporating an automated h-FABP assay, facilitating use in clinical settings. The effectiveness of this refined rule should be verified in an interventional trial prior to implementation. TRIAL REGISTRATION NUMBER: UK CRN 8376. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
acute coronary syndrome; cardiac care, diagnosis; diagnosis
Authors: Richard Body; Charles Boachie; Alex McConnachie; Simon Carley; Patricia Van Den Berg; Fiona E Lecky Journal: Emerg Med J Date: 2017-05-12 Impact factor: 2.740
Authors: Richard Rezar; Peter Jirak; Martha Gschwandtner; Rupert Derler; Thomas K Felder; Michael Haslinger; Kristen Kopp; Clemens Seelmaier; Christina Granitz; Uta C Hoppe; Michael Lichtenauer Journal: J Clin Med Date: 2020-01-07 Impact factor: 4.241
Authors: Katharine A Kott; Michael Bishop; Christina H J Yang; Toby M Plasto; Daniel C Cheng; Adam I Kaplan; Louise Cullen; David S Celermajer; Peter J Meikle; Stephen T Vernon; Gemma A Figtree Journal: Cells Date: 2022-02-08 Impact factor: 6.600
Authors: Abdulrhman Alghamdi; Eloïse Cook; Edward Carlton; Aloysius Siriwardena; Mark Hann; Alexander Thompson; Angela Foulkes; John Phillips; Jamie Cooper; Steve Bell; Kim Kirby; Andy Rosser; Richard Body Journal: BMJ Open Date: 2019-10-28 Impact factor: 2.692
Authors: Richard Body; Edward Carlton; Matthew Sperrin; Philip S Lewis; Gillian Burrows; Simon Carley; Garry McDowell; Iain Buchan; Kim Greaves; Kevin Mackway-Jones Journal: Emerg Med J Date: 2016-08-26 Impact factor: 2.740